◎ Sugi Atlas

Atlas / Disease / Alcohol withdrawal

Alcohol withdrawal

disease
On this page

Also known as alcohol withdrawal syndrome

Summary

Alcohol withdrawal (MONDO:0005433) is a disease with 1 cohort gene (1 GWAS associations across 3 studies) and 56 clinical trials. Top therapeutic interventions include lorazepam, baclofen, and diazepam.

At a glance

  • Cohort genes: 1
  • GWAS associations: 1
  • Clinical trials: 56

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namealcohol withdrawal
Mondo IDMONDO:0005433
EFOEFO:0004777
ICD-11998231424
SNOMED CT191480000
UMLSC0236663
MedGen536543
Is cancer (heuristic)no

Also known as: alcohol withdrawal syndrome

Data availability: 1 GWAS association (3 studies).

Disease family

An umbrella term covering 1 Mondo subtype.

Classification path: disease › human disease › disease by body system or component › syndromic disease › substance withdrawal syndrome › alcohol withdrawal

Related subtypes (2): neonatal abstinence syndrome, baclofen withdrawal syndrome

Subtypes (1): alcohol withdrawal delirium

Genetics & variants

GWAS landscape

1 GWAS associations across 3 studies. Top hits map to 1 distinct genes (as reported by GWAS).

Top associations by p-value

rsIDp-valueGeneRisk alleleOdds ratio
rs117310034e-09SORCS2T0.9

Top studies (by case count)

StudyLead authorYearCasesControlsTitle
GCST001319Wang KS20114610Genome-wide association study identifies 5q21 and 9p24.1 (KDM4C) loci associated with alcohol withdrawal symptoms.
GCST008136Smith AH201800Risk locus identification ties alcohol withdrawal symptoms to SORCS2.
GCST008137Smith AH201800Risk locus identification ties alcohol withdrawal symptoms to SORCS2.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

TierVariants
Tier 1: coding0
Tier 2: splice/UTR0
Tier 3: regulatory0
Tier 4: intronic/intergenic1

MAF distribution

BucketVariants
common (>=0.05)1
low_freq (0.01-0.05)0
rare (<0.01)0
unknown0

Functional consequences

ConsequenceCount
intron_variant1

Top variants

rsIDChrPosAllelesMAFConsequenceGenep-valueTier
rs1173100347388545C>G,T0.15intron_variantSORCS24e-09Tier 4: intronic/intergenic

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 0 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

SubsetGenes
gwas_only1

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
SORCS2HGNC:16698ENSG00000184985Q96PQ0VPS10 domain-containing receptor SorCS2gwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
SORCS2VPS10 domain-containing receptor SorCS2The heterodimer formed by NGFR and SORCS2 functions as receptor for the precursor forms of NGF (proNGF) and BDNF (proBDNF).

Protein-family classification

Druggable: 1 · Difficult: 0 · Unknown: 0 · Druggable fraction: 1.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Antibody/Immunoglobulin129.2×0.034

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
SORCS2Antibody/ImmunoglobulinyesPKD_dom, VPS10, Ig-like_fold

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)1
unknown0

Top tissues across cohort

TissueCohort genes
corpus callosum1
sural nerve1
tibial nerve1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
SORCS2191ubiquitousmarkercorpus callosum, tibial nerve, sural nerve

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
SORCS21,157

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
SORCS2Q96PQ01

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 0. Enrichment computed across 1 evidence-associated genes (0 with Reactome annotation).

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
long-term synaptic depression1887.0×0.003SORCS2
neuropeptide signaling pathway1172.0×0.009SORCS2
intracellular protein transport164.8×0.015SORCS2

Therapeutics

Drugs indicated for this disease

0 approved, 3 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

DrugDevelopment status
BaclofenPhase 3 (in late-stage trials)
ChlordiazepoxidePhase 3 (in late-stage trials)
LevetiracetamPhase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Gabapentin, Lorazepam, Oxytocin.

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1

Druggability breadth: 0 of 1 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

SymbolMoleculesMax phase
SORCS200

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)0
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug1SORCS2
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug0

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
SORCS20—

Clinical trials & evidence

Clinical trials

Clinical trials: 56.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified32
PHASE49
PHASE26
PHASE34
PHASE2/PHASE33
PHASE11
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00249366PHASE4COMPLETEDTreatment of Alcohol Withdrawal in Hospital Patients
NCT01573052PHASE4COMPLETEDGabapentin vs Chlordiazepoxide for Ambulatory Alcohol Withdrawal
NCT02090504PHASE4COMPLETEDComparative Study of Gamma-hydroxy Butyrate Versus Oxazepam in the Treatment of Alcohol Withdrawal Syndrome
NCT02823977PHASE4WITHDRAWNKetamine vs. Placebo as Adjunctive Therapies for Severe Alcohol Withdrawal
NCT03012815PHASE4COMPLETEDGabapentin for Alcohol Withdrawal Syndrome
NCT03235531PHASE4UNKNOWNAssessment of Valproate on Ethanol Withdrawal
NCT03293017PHASE4UNKNOWNBaclofen in Managing Acute Alcohol Withdrawal
NCT03788889PHASE4WITHDRAWNAlcohol Withdrawal Syndrome Treated With Adjunctive Phenobarbital or Ketamine
NCT04156464PHASE4UNKNOWNPhenobarbital vs Ativan for Alcohol Withdrawal in the Intensive Care Unit
NCT06173973PHASE2/PHASE3ENROLLING_BY_INVITATIONEffects of Ketone Supplementation on Acute Alcohol Withdrawal
NCT06559995PHASE2/PHASE3RECRUITINGEffects of Ketone Supplementation on Alcohol Withdrawal and Brain Metabolism in Alcohol Use Disorder
NCT00136617PHASE3COMPLETEDOutpatient Treatment of Alcohol Withdrawal Syndrome
NCT00146471PHASE3COMPLETEDEfficacy and Safety of Levetiracetam in the Inpatient Treatment of Alcohol Withdrawal Syndrome
NCT02052440PHASE3TERMINATEDPreventing Alcohol Withdrawal Syndrome With Oral Baclofen
NCT03033823PHASE3COMPLETEDMAGnesium Adjunction in Alcohol Withdrawal Syndrome: a Multicenter Assessment (MAGMA)
NCT03466528PHASE2/PHASE3COMPLETEDAlcohol: Thiamine and or Magnesium 1
NCT04793685PHASE2RECRUITINGPrazosin for Alcohol Use Disorder With Withdrawal Symptoms
NCT00229125PHASE2COMPLETEDComparing the Treatment of Alcohol Withdrawal Syndrome Using Gabapentin Versus Lorazepam
NCT01937364PHASE2TERMINATEDPreventing Alcohol Withdrawal With Oral Baclofen
NCT02275611PHASE2COMPLETEDOxytocin Treatment of Alcohol Dependence
NCT02349477PHASE2COMPLETEDGabapentin for Alcohol Relapse Prevention
NCT04232800PHASE2UNKNOWNRiboflavin for Glutamate Reduction in Alcohol Withdrawal
NCT01212185PHASE1COMPLETEDOxytocin Treatment of Alcohol Withdrawal
NCT04205682EARLY_PHASE1UNKNOWNCannabidiol (CBD) for the Treatment of Alcohol Withdrawal
NCT06589973Not specifiedRECRUITINGEffect of Clinical and Biochemical Variables Over Morbidity and Mortality in Alcohol Withdrawal Syndrome Patients
NCT06618755Not specifiedRECRUITINGMotivational Interviews Post Hospitalisation on Maintaining AbstiNence for 1 Year après le Sevrage en Alcool
NCT06675539Not specifiedRECRUITINGValidation of the French Version of the Prediction of the Alcohol Withdrawal Severity Scale (PAWSS)
NCT06771037Not specifiedRECRUITINGUse of tAN® in Alcohol Withdrawal Management
NCT06840652Not specifiedENROLLING_BY_INVITATIONSafety & Efficacy of Baclofen for Alcohol Withdrawal in Chronic Liver Disease With Active Alcohol Consumption
NCT06878287Not specifiedRECRUITINGBright Light Therapy During Residential Alcohol Withdrawal
NCT07444255Not specifiedNOT_YET_RECRUITINGComparison of the Effect on Anxiety of Combining Hypnosis and Aromatherapy Through Olfactory Anchoring Versus Standard Care in Patients Undergoing Alcohol Withdrawal
NCT00523185Not specifiedCOMPLETEDA Comparison of Lorazepam and Diazepam in the Treatment of Alcohol Withdrawal
NCT00936377Not specifiedCOMPLETEDDexmedetomidine as Adjunctive Therapy for Alcohol Withdrawal
NCT01184417Not specifiedCOMPLETEDPhenobarbital for Acute Alcohol Withdrawal
NCT01637415Not specifiedCOMPLETEDThe Prediction of Alcohol Withdrawal Severity Scale (PAWSS)
NCT01652326Not specifiedCOMPLETEDClinical Quality Improvement of Benzodiazepine-Resistant Alcohol Withdrawal Syndrome
NCT02146716Not specifiedCOMPLETEDAssessment of Energetic Resonance by Cutaneous Stimulation on Withdrawal Alcohol Symptoms.
NCT02202148Not specifiedCOMPLETEDLiver Stiffness Measurement in Alcohol-dependent Subjects in Relation to Abstinence After Withdrawal
NCT02835365Not specifiedCOMPLETEDObservational Study on Patients With Baclofen Treatment for Alcohol-dependence in France
NCT03521115Not specifiedCOMPLETEDFamily Based Prevention of Alcohol and Risky Sex for Older Teens

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
LORAZEPAM46
BACLOFEN44
DIAZEPAM44
GABAPENTIN44
VALPROIC ACID44
PHENOBARBITAL43
PRAZOSIN43
CHLORDIAZEPOXIDE42
LEVETIRACETAM41
MAGNESIUM SULFATE41
OXAZEPAM41
RIBOFLAVIN41
MAGNESIUM31
ETIRACETAM21
CHEMBL51156501
CHEMBL526727901
LEVITIRACETAM01

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 65

This page pulls from 65 datasets indexed by BioBTree:

alphafoldantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticscellosauruschembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsclinvarctd_gene_interactiondbsnpdepmapdiamond_similarityefoensemblentrezesm2_similarityfantom5_genefantom5_promotergenccgenerifgogtopdbgwasgwas_studyhgncicd11intactinterpromedgenmeshmimmondomondochildmondoparentorphanetpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assayreactomerefseqrhearnacentralsctidscxa_expressionscxa_gene_experimentsignorstring_interactiontranscriptufeatureumlsuniprot